Does Wegovy make you feel depressed — or is that a myth?

The misconception worth clearing up first

A lot of people searching this question have heard something like: "GLP-1 medicines mess with your mental health." It is a reasonable worry, partly because GLP-1 receptors exist in the brain as well as the gut, and partly because an older weight-loss drug (rimonabant, withdrawn in 2008) did carry serious psychiatric risks. Semaglutide is a different mechanism entirely. The STEP 1 trial, which ran for 68 weeks and involved over 1,900 adults, monitored participants carefully for psychiatric adverse events and did not find a significant difference in depression or anxiety rates between the semaglutide group and placebo. That is the evidence base underlying semaglutide's current UK licensing, and it is the most relevant starting point for this question.

The NHS medicines page for semaglutide does list mood changes and depressive symptoms among possible side effects. Listing something as a possible effect is not the same as saying it is common or proven causal. It means it has been reported by some patients and warrants monitoring. That distinction matters, and it gets lost in a lot of online discussion.

There is also an active question in research about whether GLP-1 medicines might actually have a positive effect on mood for some people, given receptors in brain regions involved in reward and motivation. The science is early, and no claims of benefit should be overstated, but the picture is more nuanced than "Wegovy causes depression."

Why some people do feel low, especially early on

Mood and physical symptoms are tightly linked. In the first few weeks of treatment, nausea is the most commonly reported side effect, and feeling persistently sick is, straightforwardly, miserable. Fatigue is also common during dose adjustment. If you are eating considerably less than usual, getting poor sleep because of nausea, and feeling flat, that is not necessarily the medicine acting on your brain's mood centres. It is often the predictable result of your body adjusting to a significant change.

The titration schedule exists partly for this reason. Treatment starts at the lowest dose, giving your system time to adapt before the dose increases. A clinician prescribing through a regulated service reviews your response at each stage, that review matters, because if early side effects are severe or mood is genuinely deteriorating, a slower titration or a different approach may be the right call.

It is also worth knowing that depression and obesity are independently associated. People carrying significant excess weight often experience low mood related to the condition itself, social factors, or physical discomfort. Starting treatment can surface those feelings, or the adjustment period can temporarily worsen them, without the medicine itself being the direct cause.

If you are thinking about what treatment might cost and whether private prescribing is practical, the Wegovy pricing page gives a factual overview of what private prescriptions typically involve.

When to take mood changes seriously, and what to do

None of the above means mood changes should be dismissed. A few situations warrant prompt contact with your prescriber or GP.

Seek medical help quickly if you notice persistent low mood lasting more than a couple of weeks, feelings of hopelessness, significant changes in sleep beyond the early nausea period, or any thoughts of self-harm. These symptoms need clinical attention regardless of whether the medicine is responsible. You can also report any suspected side effects directly through the MHRA's Yellow Card scheme, which helps regulators monitor medicines in the real world after approval.

There is a separate and genuinely useful question, whether low mood experienced during treatment tends to resolve as the body adapts. For adjustment-related low mood tied to nausea and early side effects, the answer is usually yes, as symptoms settle over several weeks. For mood that persists or worsens, that conversation belongs with a clinician, not a website.

The NHS semaglutide medicines page lists the full side-effect profile, including the distinction between common, uncommon and rare reported effects. It is the right reference if you want to see how mood-related reports are categorised officially.

What this means in practice if you are considering treatment

A personal or family history of depression or anxiety does not automatically rule out semaglutide. It does mean it should be part of the conversation at consultation. A GPhC-registered prescriber reviews your medical history before any prescription, not a form that auto-approves, but a clinician who reads your answers and makes a judgment. That process exists precisely for situations like this.

People who have a history of serious psychiatric illness, including active suicidal ideation, would typically need additional specialist input before starting any weight-loss medicine, and if you are exploring which product is right for you, our page covering Driada semaglutide explains how that particular formulation fits into the broader treatment landscape. That assessment cannot happen on a website; it requires a clinical conversation.

If you have questions about how our prescribers approach this or what the consultation covers, the about us page explains how the service is structured. The consultation is free, there is no obligation, and it is the right place for individual questions about your own situation. Check your eligibility and start that conversation when you are ready.